申请人:Pfizer Inc.
公开号:US05843972A1
公开(公告)日:1998-12-01
The present invention relates to certain compounds of the formula (I) the racemic-enantiomeric mixtures and optical isomers of said compounds and the pharmaceutically acceptable salts or prodrugs thereof, depicted below, which are .beta.-adrenergic receptor agonists and accordingly have utility as, inter alia, hypoglycemic and antiobesity agents. More specifically, the compounds of the instant invention are selective agonists of .beta..sub.3 -adrenergic receptor. The invention also relates to methods of use for the compounds and to pharmaceutical compositions containing them. The compounds of the present invention also possess utility for increasing lean meat deposition and/or improving the lean meat to fat ratio in animals, e.g., ungulate animals, companion animals and poultry. The compounds have the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, Y and Z are as defined in the specification.
本发明涉及以下公式(I)的某些化合物,其为该化合物的外消旋混合物和光学异构体以及其药学上可接受的盐或前药,如下图所示,这些化合物是β-肾上腺素受体激动剂,因此具有降糖和抗肥胖剂等用途。更具体地说,本发明的化合物是β3-肾上腺素受体的选择性激动剂。本发明还涉及这些化合物的使用方法以及含有它们的药物组合物。本发明的化合物还具有增加瘦肉沉积和/或改善动物(例如有蹄动物、伴侣动物和家禽)的瘦肉与脂肪比例的用途。这些化合物的公式如下:
其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、Y和Z如规范中所定义。